Coya Therapeutics Inc (COYA) Stock Price, Quote & News

Company Profile

Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary therapies to enhance the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase...

Industry: Biotechnology

Sector: Healthcare

Phone: 800 587 8170

Website: coyatherapeutics.com

Address:

5850 San Felipe St., Suite 500, Houston, United States

prismmarketview Jul. 23 at 12:50 PM

Watch #CoyaTherapeutics (NASDAQ: $COYA) CEO Arun Swaminathan, Ph.D. discuss key 2025 milestones as the company advances Treg-targeted therapies for ALS, FTD, Parkinson’s & Alzheimer’s. . https://prismmarketview.com/companies/coya-therapeutics-inc-2/

0 · Reply

Jwa68 Jul. 22 at 1:56 AM

$GANX $COYA Good news out of the FDA. Stanford faculty member George Tidmarsh, M.D., Ph.D. named Director of Center for Drug Evaluation and Research. Dr. Tidmarsh has led the successful clinical development of seven FDA-approved drugs and served as founder and CEO of multiple biopharmaceutical companies focused on oncology and critical care medicine. His work spans the full translational pipeline—from discovery through regulatory approval—and he is widely recognized for his ability to bring forward innovative treatments that address serious unmet medical needs. He has also served on advisory boards across academia, government, and industry https://www.fda.gov/news-events/press-announcements/stanford-faculty-member-george-tidmarsh-md-phd-named-director-center-drug-evaluation-and-research

1 · Reply

irf944 Jul. 21 at 2:50 PM

$COYA Added. We rae at the bottom of a Falling Wedge pattern. A falling wedge pattern is a bullish chart pattern that can signal a potential reversal of a downtrend or a continuation of an uptrend. Reduced volatility while prices have been consolidating in the most recent period. Targets are in the mid $6S Expecting results very shortly for IND filing. Low float, no debt, plenty of cash, deal in place with Dr. Reddy. Very favorable risk/reward ratio.

1 · Reply

Wolfenden15 Jul. 17 at 12:32 PM

$COYA why is this bearish all of a sudden. This should be over $10 easy!

2 · Reply

Robby83 Jul. 16 at 7:09 PM

$COYA sadly we've got technical sell reversal on the daily when it was quite possibly gearing for a breakout. None the less good day of a couple buys.

2 · Reply

Jwa68 Jul. 16 at 2:57 PM

$COYA Remains one of my favorite small hios that I believe offers highly favorable asymmetric risk and run by high quality management.

0 · Reply

Robby83 Jul. 14 at 9:02 PM

$COYA peppering more orders in the event of a bigger dip.

0 · Reply

irf944 Jul. 14 at 8:00 PM

$COYA The balance sheet stats is one of th reasons I remain so Bullish on Coya. $35M in Cash, no debt, Book value per share is $2.00, working capital $34M They have a deal in place with Dr. Reddy which will likely add more cash to the balance sheet within 30 days. Good results from the IND and I think it's only a matter of time before Dr. Reddy buys them. Cheaper for Dr. Reddy to acquire them to pay off the royalt amounts. Stock chart also looking pretty good....we broke thru the $6 resistance. Can be in the $7S when volume comes in. Float is only 13M shares.

1 · Reply

Jwa68 Jul. 14 at 1:18 AM

$COYA Big fan of Arun both personally and professionally. Proven deal guy with a strong track record.

1 · Reply

McNallieMoney Jul. 12 at 1:45 PM

$COYA $COYA new ceo interview from COYA! https://youtu.be/IKdQqWEgPys

0 · Reply

Coya Therapeutics to Participate in the BTIG Virtual Biotechnology Conference July 29 – 30, 2025

Jun 18, 2025, 8:15 AM EDT - 5 weeks ago

Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025

Jun 2, 2025, 8:00 AM EDT - 7 weeks ago

Coya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (rh) Interleukin-2 (aldesleukin) Liquid Formulations

May 16, 2025, 10:53 AM EDT - 2 months ago

Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 13, 2025, 8:00 AM EDT - 2 months ago

Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update

May 8, 2025, 8:15 AM EDT - 2 months ago

Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025

May 8, 2025, 5:00 AM EDT - 2 months ago

Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

REPL

Apr 25, 2025, 11:27 AM EDT - 3 months ago

Coya Therapeutics: Treg Proof-Of-Concept Continues With Interim FTD Data Release

Apr 24, 2025, 8:15 AM EDT - 3 months ago

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia

Apr 21, 2025, 9:51 AM EDT - 3 months ago

Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)

Apr 1, 2025, 8:15 AM EDT - 4 months ago

Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025

Mar 26, 2025, 8:15 AM EDT - 4 months ago

Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program

Mar 18, 2025, 8:15 AM EDT - 4 months ago

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results

Feb 25, 2025, 8:15 AM EST - 5 months ago

Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer's Disease Using GLP-1 Agonists and Combinations

Feb 7, 2025, 5:17 PM EST - 5 months ago

Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD

Feb 7, 2025, 1:53 PM EST - 5 months ago

Coya: A Few Catalysts On The Way For COYA-302 Makes This A Must Watch

Feb 6, 2025, 1:30 PM EST - 5 months ago

Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing

Feb 6, 2025, 8:00 AM EST - 5 months ago

Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer's Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development

Feb 4, 2025, 8:15 AM EST - 6 months ago

Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 21, 2025, 8:15 AM EST - 6 months ago

Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases

Dec 18, 2024, 8:15 AM EST - 7 months ago

Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)

Nov 25, 2024, 8:15 AM EST - 8 months ago

Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference

Nov 19, 2024, 8:15 AM EST - 8 months ago

Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders

Nov 6, 2024, 8:00 AM EST - 9 months ago

Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results

Nov 1, 2024, 8:15 AM EDT - 9 months ago

Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer

Oct 31, 2024, 10:31 AM EDT - 9 months ago

Coya Therapeutics: Buying The Dip After Unwarranted Sell-Off

Oct 29, 2024, 2:36 PM EDT - 9 months ago

Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study

Oct 29, 2024, 6:41 AM EDT - 9 months ago

Coya Therapeutics reports positive immune response, safety in mid-stage Alzheimer's drug trial

Oct 29, 2024, 6:30 AM EDT - 9 months ago

Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer's Disease (AD) Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid (Spain)

Oct 28, 2024, 8:00 AM EDT - 9 months ago

Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer's Disease

Oct 23, 2024, 4:05 PM EDT - 9 months ago

Coya Therapeutics Announces Closing of $10.0 Million Private Placement

Oct 22, 2024, 9:00 AM EDT - 9 months ago

Coya Therapeutics Announces $10.0 Million Private Placement

Oct 13, 2024, 4:17 AM EDT - 10 months ago

Coya Therapeutics Has Several Near-Term Share Price Appreciation Catalysts

Oct 8, 2024, 9:15 AM EDT - 10 months ago

Coya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100

Sep 24, 2024, 8:15 AM EDT - 10 months ago

Coya Therapeutics to Participate in Fireside Chat at the Chardan 8th Annual Genetic Medicines Conference

Sep 16, 2024, 8:15 AM EDT - 11 months ago

Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson's Disease

Sep 3, 2024, 8:15 AM EDT - 11 months ago

Coya Therapeutics to Present at Upcoming Healthcare Conferences

Aug 19, 2024, 9:00 AM EDT - 1 year ago

Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024

Aug 12, 2024, 8:00 AM EDT - 1 year ago

Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results

Aug 2, 2024, 8:15 AM EDT - 1 year ago

Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer's Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid

Jul 31, 2024, 8:15 AM EDT - 1 year ago

Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

Jun 20, 2024, 8:15 AM EDT - 1 year ago

Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic

Jun 11, 2024, 8:15 AM EDT - 1 year ago

Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology

Jun 10, 2024, 2:55 PM EDT - 1 year ago

Coya Therapeutics: Potential Milestone For The Treatment Of Alzheimer's This Summer

Jun 3, 2024, 8:15 AM EDT - 1 year ago

Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology

May 28, 2024, 8:15 AM EDT - 1 year ago

Coya Therapeutics Announces Inclusion in the MSCI USA Micro Cap Index

May 23, 2024, 3:40 PM EDT - 1 year ago

Coya Therapeutics (COYA) CEO on $5M Alzheimer's Drug Discovery Foundation Investment

May 22, 2024, 8:15 AM EDT - 1 year ago

Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer's Disease

May 20, 2024, 8:15 AM EDT - 1 year ago

Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer's Drug Discovery Foundation (ADDF)

May 9, 2024, 4:10 PM EDT - 1 year ago

Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results

prismmarketview Jul. 23 at 12:50 PM

0 · Reply

Jwa68 Jul. 22 at 1:56 AM

1 · Reply

irf944 Jul. 21 at 2:50 PM

1 · Reply

Wolfenden15 Jul. 17 at 12:32 PM

$COYA why is this bearish all of a sudden. This should be over $10 easy!

2 · Reply

Robby83 Jul. 16 at 7:09 PM

$COYA sadly we've got technical sell reversal on the daily when it was quite possibly gearing for a breakout. None the less good day of a couple buys.

2 · Reply

Jwa68 Jul. 16 at 2:57 PM

$COYA Remains one of my favorite small hios that I believe offers highly favorable asymmetric risk and run by high quality management.

0 · Reply

Robby83 Jul. 14 at 9:02 PM

$COYA peppering more orders in the event of a bigger dip.

0 · Reply

irf944 Jul. 14 at 8:00 PM

1 · Reply

Jwa68 Jul. 14 at 1:18 AM

$COYA Big fan of Arun both personally and professionally. Proven deal guy with a strong track record.

1 · Reply

McNallieMoney Jul. 12 at 1:45 PM

$COYA $COYA new ceo interview from COYA! https://youtu.be/IKdQqWEgPys

0 · Reply

Jwa68 Jul. 11 at 5:31 AM

$COYA Expecting some new eyes on this one. Deeply under appreciated in my eyes. 50% approximate discount to what i could logically compose as a current FMV. Dydd

0 · Reply

Robby83 Jul. 10 at 7:05 PM

$COYA primed for a breakout. Just needs a little catalyst. Daily and weekly charts.

1 · Reply

NickB01 Jul. 10 at 4:47 PM

$COYA stock just moved above 200 day ma. Would like to see it hold and continue to run for a bit.

0 · Reply

Apiker Jul. 10 at 3:34 PM

$COYA red brick wall on the 50Ema weekly. Has a chance to make a run if it gets thru!

0 · Reply

Chrissytina Jul. 10 at 2:31 PM

$COYA I don’t know who does the charts here, they’re never right, sometimes the prices are 🤷🏼‍♀️

0 · Reply

Jwa68 Jul. 10 at 12:55 PM

$COYA Severely undervalued. Couple weeks on potential IND acceptance and milestone payment, followed by first patient dosed and qnother milestone....ultimately leading to likely acquisition, best guess Q1 26

0 · Reply

Robby83 Jul. 9 at 5:29 PM

$COYA can we please stay over $10?

1 · Reply

JarvisFlow Jul. 9 at 1:52 PM

Lake Street has updated their rating for Coya Therapeutics ( $COYA ) to Buy with a price target of 16.

1 · Reply

Jwa68 Jul. 9 at 1:42 PM

$COYA Incredible asymmetric risk here.

1 · Reply

G101SPM Jul. 9 at 12:53 PM

$COYA $6.19 bid DAC $6.19 (12.4.24). EXIT $11.00. ... from the other side: Lake Street initiates COYA with a Buy and price target of $16. Analyst Chad Messer added, "Aberrant inflammation is the root cause of a plethora of chronic illnesses. To help address this issue, Coya utilizes a disease pathway agnostic approach that uses low dose IL-2 to increase the number and function of regulatory T cells (Tregs). Tregs are a special set of anti-inflammatory T cells that are critical to immune homeostasis. IL-2 is an important cytokine that stimulates T cell proliferation. Abatacept, sold under the brand name Orencia, was approved in 2005 to treat inflammatory conditions such as rheumatoid arthritis and GvHD. Coya's lead program, COYA-302, is a combination of low dose IL-2 and a biosimilar version of abatacept. COYA-302 is partnered in North America and Europe for amyotrophic lateral sclerosis (ALS) with Dr Reddy's Laboratories, who also supplies biosimilar CTLA-4-Ig."

0 · Reply

irf944 Jul. 7 at 6:47 PM

$COYA Added on the dip.

0 · Reply

Jwa68 Jul. 7 at 3:34 PM

$COYA I could make a very persuasive argument that the shares fair value as we speak, should be easily $8 conservatively.

1 · Reply

Market Cap	96.67M
Revenue (ttm)	3.55M
Net Income (ttm)	-14.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-419.15%
Debt to Equity Ratio	0.00

Volume	65,100
Avg Vol	56,616
Day's Range	N/A - N/A
Shares Out	16.73M
Stochastic %K	4%
Beta	0.26
Analysts	Strong Sell
Price Target	$16.20